Clinical Trial Update: Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612) [Phase 3]

View source ↗

Summary

Phase 3 trial SPI-612 evaluated a single-dose intravesical apaziquone after TURBT for non-muscle-invasive bladder cancer; results have been posted upon completi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Apaziquone (apaziquone)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Bladder Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-08-15